Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04312113 · ClinicalTrials.gov registry record · Phase 1
Angiographic Delivery of AD-MSC for Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04312113: Active Phase 1 study of Ulcerative Colitis, sponsored by Mayo Clinic.
NCT04312113 is a Phase 1 study of Ulcerative Colitis that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04312113, a Phase 1 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are trying to determine the safety and feasibility of using an adipose derived mesenchymal stem cell (MSC) to treat people with Ulcerative Colitis.
Primary Outcome
Evaluate safety by assessment of adverse events defined as worsening (change in nature, severity, or frequency of bowel movements, bleeding per rectum, or tenesmus) of UC present at the time of the study, intercurrent illnesses, abnormal laboratory values (this includes clinically significant shifts from baseline within the range of normal that the investigator considers to be clinically significant) or clinically significant abnormalities in physical examination, vital signs, weight, frequency
Conditions Studied
Interventions
- DRUG Adipose derived, autologous mesenchymal stem cells
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT04312113 still lists
NCT04312113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Adipose derived, autologous mesenchymal stem cells is the first listed.
NCT04312113 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04312113 about?
NCT04312113 is a clinical study titled "Angiographic Delivery of AD-MSC for Ulcerative Colitis". Researchers are trying to determine the safety and feasibility of using an adipose derived mesenchymal stem cell (MSC) to treat people with Ulcerative Colitis.
What is the current status of trial NCT04312113?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-11-16. Estimated completion is 2026-12.
What conditions does trial NCT04312113 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT04312113?
The interventions under investigation include: Adipose derived, autologous mesenchymal stem cells (DRUG).
Who is sponsoring clinical trial NCT04312113?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04312113 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04312113's enrollment target sits among peer trials
20 112th of 122 higher than 8 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
-
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI